A Partnership with The Association for Frontotemporal Degeneration
The Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator initiative has announced a new $5 million commitment to projects targeting the development of biomarkers for frontotemporal degeneration (FTD), the most common dementia for people under 60. A new $2.5 million research investment from The Association for Frontotemporal Degeneration (AFTD) is being matched by a $2.5 million allocation of the ADDF’s Diagnostics Accelerator funds.
The Diagnostics Accelerator was launched in July 2018 through an initial funding commitment from philanthropists Bill Gates, ADDF co-founder Leonard Lauder, and others, including the Dolby family and the Charles and Helen Schwab Foundation, who share their commitment to combating the rising burden of Alzheimer’s disease and related…
